FTO/BCL6 Axis Identified as Therapeutic Target in Gastric Cancer Progression
FTO-mediated demethylation of BCL6 promotes gastric cancer progression by inhibiting ferroptosis.
Asset / Drug
Drug and asset intelligence for BCL6 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.